Effectiveness of natriuretic peptide-guided treatment of chronic heart failure. A meta-analysis

被引:2
|
作者
Gamino-Arroyo, Ana-Estela [1 ]
Prado-Galbarro, Francisco-Javier [2 ,3 ,4 ]
Garcia-Perez, Sonia [4 ,5 ]
Sanchez-Piedra, Carlos [4 ]
机构
[1] Hosp Infantil Mexico Dr Federico Gomez, Unidad Infectol, Ciudad De Mexico, Mexico
[2] Inst Nacl Enfermedades Resp, Ctr Invest Enfermedades Infecciosas, Ciudad De Mexico, Mexico
[3] Inst Nacl Salud Publ, Unidad Salud Reprod, Cuernavaca, Morelos, Mexico
[4] Inst Salud Carlos III, Agencia Evaluac Tecnol Sanitarias, Madrid, Spain
[5] REDISSEC, Unidad Invest, Madrid, Spain
来源
ARCHIVOS DE CARDIOLOGIA DE MEXICO | 2018年 / 88卷 / 03期
关键词
Heart failure; Natriuretic peptide; Meta-analysis; Therapy; NT-proBNP; Mexico;
D O I
10.1016/j.acmx.2017.02.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To evaluate the efficacy of natriuretic peptide (NP)-guided therapy compared to clinically-guided therapy in reducing mortality and hospital admissions in chronic heart failure (HF) patients. Methods: Randomised clinical trials (RCT) were selected through a systematic review. Four meta-analyses were conducted for the outcomes of overall mortality, HF-related mortality, overall hospital admissions, and HF-related hospital admissions. Heterogeneity between studies and publication bias were also assessed. Results: Nine RCTs were found with a total of 1914 patients. NP-guided therapy significantly reduced overall mortality and HF-related hospital admissions. No significant results were found for HF-related mortality and overall hospital admissions. Some clinical heterogeneity regarding interventions performed was found between studies. Publication bias was found for HF-related and overall hospital admissions. Conclusions: NP-guided therapy seems to improve outcomes compared to clinically-guided therapy. However, heterogeneity found between interventions might reduce the generalisation of these results. Specific interventions of the clinical trials should be examined when making recommendations regarding NP-guided therapy. (C) 2017 Instituto Nacional de Cardiologia Ignacio Chavez. Published by Masson Doyma Mexico S.A.
引用
收藏
页码:171 / 177
页数:7
相关论文
共 50 条
  • [21] Cost-effectiveness of B-type natriuretic peptide-guided care in patients with heart failure: a systematic review
    Jafari, Abdosaleh
    Rezapour, Aziz
    Hajahmadi, Marjan
    HEART FAILURE REVIEWS, 2018, 23 (05) : 693 - 700
  • [22] Changes of Natriuretic Peptides Predict Hospital Admissions in Patients With Chronic Heart Failure A Meta-Analysis
    Savarese, Gianluigi
    Musella, Francesca
    D'Amore, Carmen
    Vassallo, Enrico
    Losco, Teresa
    Gambardella, Francesco
    Cecere, Milena
    Petraglia, Laura
    Pagano, Gennaro
    Fimiani, Luigi
    Rengo, Giuseppe
    Leosco, Dario
    Trimarco, Bruno
    Perrone-Filardi, Pasquale
    JACC-HEART FAILURE, 2014, 2 (02) : 148 - 158
  • [23] Does B-type natriuretic peptide-guided therapy improve outcomes in patients with chronic heart failure? A systematic review and meta-analysis of randomized controlled trials
    Wei Xin
    Zhiqin Lin
    Shuhua Mi
    Heart Failure Reviews, 2015, 20 : 69 - 80
  • [24] Does B-type natriuretic peptide-guided therapy improve outcomes in patients with chronic heart failure? A systematic review and meta-analysis of randomized controlled trials
    Xin, Wei
    Lin, Zhiqin
    Mi, Shuhua
    HEART FAILURE REVIEWS, 2015, 20 (01) : 69 - 80
  • [25] Natriuretic Peptide-Guided Heart Failure Therapy After the GUIDE-IT Study
    Januzzi, James L., Jr.
    Richards, A. Mark
    CIRCULATION, 2018, 137 (20) : 2101 - 2103
  • [26] Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure
    Mark, Daniel B.
    Cowper, Patricia A.
    Anstrom, Kevin J.
    Sheng, Shubin
    Daniels, Melanie R.
    Knight, J. David
    Baloch, Khaula N.
    Davidson-Ray, Linda
    Fiuzat, Mona
    Januzzi, James L., Jr.
    Whellan, David J.
    Pina, Ileana L.
    Ezekowitz, Justin A.
    Adams, Kirkwood F.
    Cooper, Lawton S.
    O'Connor, Christopher M.
    Felker, G. Michael
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (21) : 2551 - 2562
  • [27] Cost-effectiveness of B-type natriuretic peptide-guided care in patients with heart failure: a systematic review
    Abdosaleh Jafari
    Aziz Rezapour
    Marjan Hajahmadi
    Heart Failure Reviews, 2018, 23 : 693 - 700
  • [28] B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data
    Maria Pufulete
    Rachel Maishman
    Lucy Dabner
    Julian P. T. Higgins
    Chris A. Rogers
    Mark Dayer
    John MacLeod
    Sarah Purdy
    William Hollingworth
    Morten Schou
    Manuel Anguita-Sanchez
    Patric Karlström
    Michael Kleiner Shochat
    Theresa McDonagh
    Angus K. Nightingale
    Barnaby C. Reeves
    Systematic Reviews, 7
  • [29] B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data
    Pufulete, Maria
    Maishman, Rachel
    Dabner, Lucy
    Higgins, Julian P. T.
    Rogers, Chris A.
    Dayer, Mark
    MacLeod, John
    Purdy, Sarah
    Hollingworth, William
    Schou, Morten
    Anguita-Sanchez, Manuel
    Karlstrom, Patric
    Shochat, Michael Kleiner
    McDonagh, Theresa
    Nightingale, Angus K.
    Reeves, Barnaby C.
    SYSTEMATIC REVIEWS, 2018, 7
  • [30] The diagnostic utility of brain natriuretic peptide in heart failure patients presenting with acute dyspnea: a meta-analysis
    Mastandrea, Paolo
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2013, 51 (06) : 1155 - 1165